Enthusiasm for GLP-1 drugs on Wall Street persists, with Eli Lilly (LLY) committing more than $5.3 billion to expand a plant involved in the production of tirzepatide weight-loss and diabetes injections.

Jefferies Biotechnology Managing Director Michael Yee joins Market Domination to explain which biotech companies are hidden gems in the GLP-1 craze on Wall Street.

"We have said Amgen (AMGN) is one of the most important large-cap companies that we have been very bullish on. And they, too, will go to phase three with a monthly GLP-1. And we think the data is going to be great the end of the year. There's also smaller companies, like Scholar Rock, SRRK, or Corbis that also have new modalities that are interesting," Yee tells Yahoo Finance.

For more on the biotech sector and the upcoming annual conference for The American Society of Clinical Oncology, watch the full interview with Michael Yee here: http://goldberglawma.com/?id=video/biotech-sector-cancer-vaccines-pd-204711308.html

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Nicholas Jacobino